CorMedix Entered Into A New Commercial Supply Contract With A Top-Five Mid-Sized Dialysis Operator For The Supply Of DefenCath
Portfolio Pulse from Benzinga Newsdesk
CorMedix Inc. has signed a new commercial supply contract with a top-five mid-sized dialysis operator for its product DefenCath, expanding its reach to over 200 outpatient dialysis clinics in the US. This follows recent NDA approval and CMS reimbursement for DefenCath.
October 08, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CorMedix Inc. has entered a new supply contract for DefenCath with a major dialysis operator, expanding its market to over 200 clinics. This follows NDA approval and CMS reimbursement, indicating strong growth potential.
The new supply contract with a top dialysis operator significantly expands CorMedix's market presence for DefenCath, following recent regulatory approvals and reimbursement. This is likely to positively impact CRMD's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100